Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer.

Cancer communications (London, England)

Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L.
PMID: 34520132
Cancer Commun (Lond). 2021 Dec;41(12):1387-1397. doi: 10.1002/cac2.12205. Epub 2021 Sep 14.

BACKGROUND: DNA methylation and gene expression are known to play important roles in the etiology of human diseases such as prostate cancer (PCa). However, it has not yet been possible to incorporate information of DNA methylation and gene expression...

Cite
Wu C, Zhu J, King A, et al. Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021;41(12):1387-1397doi: 10.1002/cac2.12205.
Wu, C., Zhu, J., King, A., Tong, X., Lu, Q., Park, J. Y., Wang, L., Gao, G., Deng, H. W., Yang, Y., Knudsen, K. E., Rebbeck, T. R., Long, J., Zheng, W., Pan, W., Conti, D. V., Haiman, C. A., & Wu, L. (2021). Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer communications (London, England), 41(12), 1387-1397. https://doi.org/10.1002/cac2.12205
Wu, Chong, et al. "Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer." Cancer communications (London, England) vol. 41,12 (2021): 1387-1397. doi: https://doi.org/10.1002/cac2.12205
Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L. Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021 Dec;41(12):1387-1397. doi: 10.1002/cac2.12205. Epub 2021 Sep 14. PMID: 34520132.
Copy Download .nbib Format: NLM
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.

Journal of the National Cancer Institute

Kerns SL, Fachal L, Dorling L, Barnett GC, Baran A, Peterson DR, Hollenberg M, Hao K, Narzo AD, Ahsen ME, Pandey G, Bentzen SM, Janelsins M, Elliott RM, Pharoah PDP, Burnet NG, Dearnaley DP, Gulliford SL, Hall E, Sydes MR, Aguado-Barrera ME, Gómez-Caamaño A, Carballo AM, Peleteiro P, Lobato-Busto R, Stock R, Stone NN, Ostrer H, Usmani N, Singhal S, Tsuji H, Imai T, Saito S, Eeles R, DeRuyck K, Parliament M, Dunning AM, Vega A, Rosenstein BS, West CML.
PMID: 31095341
J Natl Cancer Inst. 2020 Feb 01;112(2):179-190. doi: 10.1093/jnci/djz075.

BACKGROUND: A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies.METHODS: We conducted an individual patient...

Cite
Kerns SL, Fachal L, Dorling L, et al. Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. J Natl Cancer Inst. 2020;112(2):179-190doi: 10.1093/jnci/djz075.
Kerns, S. L., Fachal, L., Dorling, L., Barnett, G. C., Baran, A., Peterson, D. R., Hollenberg, M., Hao, K., Narzo, A. D., Ahsen, M. E., Pandey, G., Bentzen, S. M., Janelsins, M., Elliott, R. M., Pharoah, P. D. P., Burnet, N. G., Dearnaley, D. P., Gulliford, S. L., Hall, E., Sydes, M. R., Aguado-Barrera, M. E., Gómez-Caamaño, A., Carballo, A. M., Peleteiro, P., Lobato-Busto, R., Stock, R., Stone, N. N., Ostrer, H., Usmani, N., Singhal, S., Tsuji, H., Imai, T., Saito, S., Eeles, R., DeRuyck, K., Parliament, M., Dunning, A. M., Vega, A., Rosenstein, B. S., & West, C. M. L. (2020). Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. Journal of the National Cancer Institute, 112(2), 179-190. https://doi.org/10.1093/jnci/djz075
Kerns, Sarah L, et al. "Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy." Journal of the National Cancer Institute vol. 112,2 (2020): 179-190. doi: https://doi.org/10.1093/jnci/djz075
Kerns SL, Fachal L, Dorling L, Barnett GC, Baran A, Peterson DR, Hollenberg M, Hao K, Narzo AD, Ahsen ME, Pandey G, Bentzen SM, Janelsins M, Elliott RM, Pharoah PDP, Burnet NG, Dearnaley DP, Gulliford SL, Hall E, Sydes MR, Aguado-Barrera ME, Gómez-Caamaño A, Carballo AM, Peleteiro P, Lobato-Busto R, Stock R, Stone NN, Ostrer H, Usmani N, Singhal S, Tsuji H, Imai T, Saito S, Eeles R, DeRuyck K, Parliament M, Dunning AM, Vega A, Rosenstein BS, West CML. Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. J Natl Cancer Inst. 2020 Feb 01;112(2):179-190. doi: 10.1093/jnci/djz075. PMID: 31095341; PMCID: PMC7019089.
Copy Download .nbib Format: NLM
Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer.

Oncotarget

Loveday C, Litchfield K, Levy M, Holroyd A, Broderick P, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N, Reid A, Huddart RA, Houlston RS, Turnbull C.
PMID: 29560096
Oncotarget. 2017 Dec 07;9(16):12630-12638. doi: 10.18632/oncotarget.23117. eCollection 2018 Feb 27.

Testicular germ cell tumor (TGCT), the most common cancer in men aged 18 to 45 years, has a strong heritable basis. Genome-wide association studies (GWAS) have proposed single nucleotide polymorphisms (SNPs) at a number of loci influencing TGCT risk....

Cite
Loveday C, Litchfield K, Levy M, et al. Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. Oncotarget. 2017;9(16):12630-12638doi: 10.18632/oncotarget.23117.
Loveday, C., Litchfield, K., Levy, M., Holroyd, A., Broderick, P., Kote-Jarai, Z., Dunning, A. M., Muir, K., Peto, J., Eeles, R., Easton, D. F., Dudakia, D., Orr, N., Pashayan, N., Reid, A., Huddart, R. A., Houlston, R. S., & Turnbull, C. (2018). Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. Oncotarget, 9(16), 12630-12638. https://doi.org/10.18632/oncotarget.23117
Loveday, Chey, et al. "Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer." Oncotarget vol. 9,16 (2018): 12630-12638. doi: https://doi.org/10.18632/oncotarget.23117
Loveday C, Litchfield K, Levy M, Holroyd A, Broderick P, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N, Reid A, Huddart RA, Houlston RS, Turnbull C. Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. Oncotarget. 2017 Dec 07;9(16):12630-12638. doi: 10.18632/oncotarget.23117. eCollection 2018 Feb 27. PMID: 29560096; PMCID: PMC5849160.
Copy Download .nbib Format: NLM
Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer.

Cancer communications (London, England)

Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L.
PMID: 34520132
Cancer Commun (Lond). 2021 Dec;41(12):1387-1397. doi: 10.1002/cac2.12205. Epub 2021 Sep 14.

BACKGROUND: DNA methylation and gene expression are known to play important roles in the etiology of human diseases such as prostate cancer (PCa). However, it has not yet been possible to incorporate information of DNA methylation and gene expression...

Cite
Wu C, Zhu J, King A, et al. Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021;41(12):1387-1397doi: 10.1002/cac2.12205.
Wu, C., Zhu, J., King, A., Tong, X., Lu, Q., Park, J. Y., Wang, L., Gao, G., Deng, H. W., Yang, Y., Knudsen, K. E., Rebbeck, T. R., Long, J., Zheng, W., Pan, W., Conti, D. V., Haiman, C. A., & Wu, L. (2021). Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer communications (London, England), 41(12), 1387-1397. https://doi.org/10.1002/cac2.12205
Wu, Chong, et al. "Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer." Cancer communications (London, England) vol. 41,12 (2021): 1387-1397. doi: https://doi.org/10.1002/cac2.12205
Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L. Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021 Dec;41(12):1387-1397. doi: 10.1002/cac2.12205. Epub 2021 Sep 14. PMID: 34520132; PMCID: PMC8696216.
Copy Download .nbib Format: NLM
A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk.

International journal of cancer

Liu D, Zhu J, Zhou D, Nikas EG, Mitanis NT, Sun Y, Wu C, Mancuso N, Cox NJ, Wang L, Freedland SJ, Haiman CA, Gamazon ER, Nikas JB, Wu L.
PMID: 34520569
Int J Cancer. 2022 Jan 01;150(1):80-90. doi: 10.1002/ijc.33808. Epub 2021 Sep 25.

A large proportion of heritability for prostate cancer risk remains unknown. Transcriptome-wide association study combined with validation comparing overall levels will help to identify candidate genes potentially playing a role in prostate cancer development. Using data from the Genotype-Tissue...

Cite
Liu D, Zhu J, Zhou D, et al. A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. Int J Cancer. 2021;150(1):80-90doi: 10.1002/ijc.33808.
Liu, D., Zhu, J., Zhou, D., Nikas, E. G., Mitanis, N. T., Sun, Y., Wu, C., Mancuso, N., Cox, N. J., Wang, L., Freedland, S. J., Haiman, C. A., Gamazon, E. R., Nikas, J. B., & Wu, L. (2022). A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. International journal of cancer, 150(1), 80-90. https://doi.org/10.1002/ijc.33808
Liu, Duo, et al. "A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk." International journal of cancer vol. 150,1 (2022): 80-90. doi: https://doi.org/10.1002/ijc.33808
Liu D, Zhu J, Zhou D, Nikas EG, Mitanis NT, Sun Y, Wu C, Mancuso N, Cox NJ, Wang L, Freedland SJ, Haiman CA, Gamazon ER, Nikas JB, Wu L. A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. Int J Cancer. 2022 Jan 01;150(1):80-90. doi: 10.1002/ijc.33808. Epub 2021 Sep 25. PMID: 34520569; PMCID: PMC8595764.
Copy Download .nbib Format: NLM
No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease.

Journal of Parkinson's disease

Senkevich K, Bandres-Ciga S, Yu E, Liyanage UE, Noyce AJ, Gan-Or Z.
PMID: 33646179
J Parkinsons Dis. 2021;11(2):801-809. doi: 10.3233/JPD-202474.

BACKGROUND: Epidemiological data suggest that cancer patients have a reduced risk of subsequent Parkinson's disease (PD) development, but the prevalence of PD in melanoma patients is often reported to be increased. Causal relationships between cancers and PD have not...

Cite
Senkevich K, Bandres-Ciga S, Yu E, et al. No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease. J Parkinsons Dis. 2021;11(2):801-809doi: 10.3233/JPD-202474.
Senkevich, K., Bandres-Ciga, S., Yu, E., Liyanage, U. E., Noyce, A. J., & Gan-Or, Z. (2021). No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease. Journal of Parkinson's disease, 11(2), 801-809. https://doi.org/10.3233/JPD-202474
Senkevich, Konstantin, et al. "No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease." Journal of Parkinson's disease vol. 11,2 (2021): 801-809. doi: https://doi.org/10.3233/JPD-202474
Senkevich K, Bandres-Ciga S, Yu E, Liyanage UE, Noyce AJ, Gan-Or Z. No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease. J Parkinsons Dis. 2021;11(2):801-809. doi: 10.3233/JPD-202474. PMID: 33646179.
Copy Download .nbib Format: NLM
Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer.

Cancer communications (London, England)

Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L.
PMID: 34520132
Cancer Commun (Lond). 2021 Dec;41(12):1387-1397. doi: 10.1002/cac2.12205. Epub 2021 Sep 14.

BACKGROUND: DNA methylation and gene expression are known to play important roles in the etiology of human diseases such as prostate cancer (PCa). However, it has not yet been possible to incorporate information of DNA methylation and gene expression...

Cite
Wu C, Zhu J, King A, et al. Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021;41(12):1387-1397doi: 10.1002/cac2.12205.
Wu, C., Zhu, J., King, A., Tong, X., Lu, Q., Park, J. Y., Wang, L., Gao, G., Deng, H. W., Yang, Y., Knudsen, K. E., Rebbeck, T. R., Long, J., Zheng, W., Pan, W., Conti, D. V., Haiman, C. A., & Wu, L. (2021). Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer communications (London, England), 41(12), 1387-1397. https://doi.org/10.1002/cac2.12205
Wu, Chong, et al. "Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer." Cancer communications (London, England) vol. 41,12 (2021): 1387-1397. doi: https://doi.org/10.1002/cac2.12205
Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L. Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021 Dec;41(12):1387-1397. doi: 10.1002/cac2.12205. Epub 2021 Sep 14. PMID: 34520132; PMCID: PMC8696216.
Copy Download .nbib Format: NLM
Association of the Lactase Persistence Haplotype Block With Disease Risk in Populations of European Descent.

Frontiers in genetics

Joslin SEK, Durbin-Johnson BP, Britton M, Settles ML, Korf I, Lemay DG.
PMID: 33193640
Front Genet. 2020 Oct 29;11:558762. doi: 10.3389/fgene.2020.558762. eCollection 2020.

Among people of European descent, the ability to digest lactose into adulthood arose via strong positive selection of a highly advantageous allele encompassing the lactase gene. Lactose-tolerant and intolerant individuals may have different disease risks due to the shared...

Cite
Joslin SEK, Durbin-Johnson BP, Britton M, et al. Association of the Lactase Persistence Haplotype Block With Disease Risk in Populations of European Descent. Front Genet. 2020;11:558762doi: 10.3389/fgene.2020.558762.
Joslin, S. E. K., Durbin-Johnson, B. P., Britton, M., Settles, M. L., Korf, I., & Lemay, D. G. (2020). Association of the Lactase Persistence Haplotype Block With Disease Risk in Populations of European Descent. Frontiers in genetics, 11558762. https://doi.org/10.3389/fgene.2020.558762
Joslin, Shannon E K, et al. "Association of the Lactase Persistence Haplotype Block With Disease Risk in Populations of European Descent." Frontiers in genetics vol. 11 (2020): 558762. doi: https://doi.org/10.3389/fgene.2020.558762
Joslin SEK, Durbin-Johnson BP, Britton M, Settles ML, Korf I, Lemay DG. Association of the Lactase Persistence Haplotype Block With Disease Risk in Populations of European Descent. Front Genet. 2020 Oct 29;11:558762. doi: 10.3389/fgene.2020.558762. eCollection 2020. PMID: 33193640; PMCID: PMC7658388.
Copy Download .nbib Format: NLM
Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer.

Cancer communications (London, England)

Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L.
PMID: 34520132
Cancer Commun (Lond). 2021 Sep 14; doi: 10.1002/cac2.12205. Epub 2021 Sep 14.

BACKGROUND: DNA methylation and gene expression are known to play important roles in the etiology of human diseases such as prostate cancer (PCa). However, it has not yet been possible to incorporate information of DNA methylation and gene expression...

Cite
Wu C, Zhu J, King A, et al. Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021;doi: 10.1002/cac2.12205.
Wu, C., Zhu, J., King, A., Tong, X., Lu, Q., Park, J. Y., Wang, L., Gao, G., Deng, H. W., Yang, Y., Knudsen, K. E., Rebbeck, T. R., Long, J., Zheng, W., Pan, W., Conti, D. V., Haiman, C. A., & Wu, L. (2021). Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer communications (London, England), . https://doi.org/10.1002/cac2.12205
Wu, Chong, et al. "Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer." Cancer communications (London, England) vol. (2021). doi: https://doi.org/10.1002/cac2.12205
Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L. Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021 Sep 14; doi: 10.1002/cac2.12205. Epub 2021 Sep 14. PMID: 34520132.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries